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Stent thrombosis (ST) after percutaneous coronary intervention has been the focus of intense interest because
of its attendant morbidity and mortality. There is controversy about several facets of the problem. These include
the frequency of ST with drug-eluting stents (DES) versus bare-metal stents (BMS), the timing of the event, clini-
cal consequences, risk factors, adjunctive therapy, and new preventive approaches. Information has accrued
rapidly from several sources, including randomized controlled clinical trials of DES versus BMS in carefully se-
lected subsets of patients and registry experiences in larger patient groups, which provide a more universal real-
world picture. The results from these different data sets are not completely concordant. However, several gen-
eral conclusions can be made: 1) ST is an infrequent but very severe complication of both BMS and DES; 2) at
the present time, during 4 years of follow-up from randomized controlled trials that compared DES and BMS,
there is no apparent difference in overall ST frequency, although the time course for occurrence appears to dif-
fer, with a relative numeric excess of ST late after DES implant; 3) despite this relative imbalance, no differ-
ences in the end points of death or death and infarction between DES and BMS are observed; 4) longer-term
follow-up of these patients as well as larger angiographic and clinical subsets of patients who receive this tech-
nology outside of randomized trials are required to fully study this issue; and 5) advances in stent platforms for
drug elution as well as adjunctive pharmacologic therapy are being evaluated to enhance long-term
safety. (J Am Coll Cardiol 2007;50:109–18) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.032D
S
o
t
a
d
a
i
e
w
c
i
p
i
T
mtent thrombosis (ST) has received considerable attention
nd is a source of considerable concern (1–16). Issues
urrounding it are complex and sometimes conflicting,
ncluding its clinical consequences, timing, relative fre-
uency compared with other technologies, risk factors, and
revention.
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everal definitions of ST have been used, clouding the issue
f incidence as well as presentation. In angiographic series,
he definition has required acute ischemic symptoms and
ngiographic documentation of Thrombolysis In Myocar-
ial Infarction (TIMI) flow grade 0 or 1 or the presence of
flow-limiting thrombus in the stented segment. This
dentifies a very select group of patients and might under-
stimate the true incidence.
“Clinically suspected ST” requires clinical presentation
ith an acute ischemic event and electrocardiographic
hanges in the distribution of the stented segment. While it
s traditional to include sudden death within 30 days of the
rocedure in the definition of ST, broader definitions now
n use include sudden unexplained death beyond 30 days.
his definition of ST is the most liberal and may overesti-
ate the incidence.
Definitions may also vary with regard to timing. Acuter subacute ST includes 1 of the previously mentioned
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occurring either during the index
procedure (acute) or within 30
days (subacute). Late ST has
been defined as occurring from
30 to 360 days after the index
procedure. Very late ST has been
defined variably as occurring ei-
ther6 months or1 year later.
Recently, a standardized defini-
tion has been proposed by the
Academic Research Consortium
(ARC) (10). Using this approach,
ome authors have suggested that definite or probable ST is the
ost accurate representation of the event (10).
linical Consequences of ST
he consequences of abrupt coronary closure after percuta-
eous coronary intervention have been well described. With
onventional balloon angioplasty, acute or threatened clo-
ure was observed in 6% to 8% of patients. In the National
eart, Lung, and Blood Institute percutaneous transluminal
oronary angioplasty (PTCA) registry 1985 to 1986 cohort,
hen occlusion occurred during the procedure, 40% of
atients developed infarction (17); this was the most im-
ortant predictor of in-hospital infarction and mortality
18). Although these data relate to conventional PTCA,
hey remain valid today for ST.
hrombosis With Different Stent Platforms
are-metal ST. The majority of studies with bare-metal
tents (BMS) reported ST only within the first 30 days. In
cumulative analysis of 8 clinical series involving almost
0,000 patients, an average incidence of ST of 1.2% (range
.4% to 2.8%) was reported through 30 days of follow-up
19). Late ST with BMS has been incompletely studied. A
ecent publication by Ferrari et al. (20) is noteworthy
ecause it documents 10 late or very late ST occurring with
MS after aspirin withdrawal. Those events occurred at 15
6.5 months after stent implantation.
When ST occurs, it is catastrophic. In one analysis of
are-metal ST, Cutlip et al. (6) found that the 30-day death
r infarction rate was 64%. Mortality was 18.9% at 30 days
nd 20.8% at 6 months. Registry reports by Karillon et al.
21) and Moussa et al. (22) of stented patients document
0-day mortality of 26% and 24%, respectively, when
hrombosis occurs. In the Orford et al. analysis (23), ST was
bserved in 0.51% of 4,509 patients who received BMS;
ith ST, 48% died and 39% had a nonfatal infarction.
rug-eluting ST. Subacute ST with drug-eluting stents
DES) remains equally serious (3–5,10–16,24–30), with
ssociated fatality rates of 40% to 50% and the composite of
eath or infarction in 50% to 70% of patients. The specific
ncidence of events varies depending on whether the defi-
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosisition was “angiographic subacute thrombosis” or “pre- Pumed clinical subacute thrombosis.” In one small series,
ng et al. (28) found that after “angiographic subacute
hrombosis,” the 30-day mortality was 15% and nonfatal
nfarction occurred in 65% of patients. After “presumed
linical subacute thrombosis,” mortality was 75% and non-
atal infarction was 25%.
Selection bias as well as the limits and assumptions about
iming of ST events and their outcomes makes categoriza-
ion and understanding difficult. Although most cases occur
uring the first 6 months, sporadic cases continue to be
eported in much later time frames (4,27–29). Because
bservational reports usually include only patients who
resent with acute syndromes, the question is raised of
hether stents may thrombose and go undetected more
requently when associated with less dramatic clinical
resentations.
The relative frequency of ST with different stent plat-
orms is of great interest. Given the unique differences
etween DES in terms of specific drug, polymer, and metal
ackbone, there may be differences in ST. Comparisons
ave been hampered by the fact that the overall event rate is
mall, and the duration of follow-up has been limited. No
andomized trials to date have been adequately powered to
valuate ST as a primary end point. Given the low event
ate, sample sizes for such a trial would be very large. The
esults of the analyses to date have documented either no
ppreciable or only a slight difference (31–33).
hrombosis in BMS versus DES. Evaluation of the
requency of ST with DES versus BMS has been difficult
9,27,28,31,33). Ideally, one would like to compare the
requency of ST in comparable patients treated with DES
ersus BMS. Such a comparison would have to overcome
he complexities of whether patients and adjunctive thera-
ies as well as definitions and surveillance programs were
imilar enough for such analyses. A major confounding
actor is that in randomized trials, which offer the best
pportunity for comparable patient and lesion demograph-
cs, mostly lower-risk patients are studied and the actual
ncidence of ST may be underestimated relative to “real
orld” post-market patient populations (15). Conversely,
wing to the lower restenosis rate, it is also clear that more
omplex lesions are being treated with DES than was the
ase with BMS.
In a pooled analysis of 10 randomized trials of DES
ersus BMS and sirolimus-eluting stents (SES) as well as
aclitaxel-eluting stents (PES) with data on 5,030 patients,
T out to 9 months occurred in 0.6% of 2,602 DES patients
nd 0.5% of 2,428 BMS patients (9). This incidence is
imilar to nonrandomized trial data previously published
ith BMS (6,23). In another meta-analysis confined to
ES, 8 trials involving 3,817 patients were analyzed (31).
he hazard ratio (HR) for ST within the first year was 1.06
95% confidence interval [CI] 0.55 to 2.04), indicating no
ignificant difference between PES and BMS. A more
ecent analysis of pooled data from the TAXUS (Taxus
aclitaxel-Eluting Stent)-II, -IV, -V, and -VI trials dem-
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July 10, 2007:109–18 Thrombosis and DES: An Objective Appraisalnstrated that between 6 months and 3 years of follow-up,
slight but statistically significant increase in ST was
bserved after Taxus versus BMS deployment (p  0.019)
34).
More recently, the results of several pooled analyses have
ecome available based on pooled patient-level data (10,12–
4). These studies have considerable overlap because the
entral component of each is the inclusion of many of the
ame randomized trials of DES versus BMS that were used
or Food and Drug Administration approval. The definition
f ST included both the protocol as well as the ARC
efinitions. The primary end points of each of these pooled
nalyses varied.
Two of these studies were restricted to trials of SES
ersus BMS. Spaulding et al. (14) evaluated 1,748 patients
or 4 trials, using as a primary safety end point 4-year
urvival, and found no difference between the 2 groups:
3.3% survival rate for SES and 94.6% for BMS (HR for
eath 1.24, 95% CI 0.84 to 1.83; p  0.28). The incidence
f death or any infarction was also not different: 11.6% for
ES versus 10.5% for BMS (p  0.48). Finally, ST rates
ere not different; using the ARC definition (10), any ST
ccurred in 30 of 878 SES patients (3.6%) versus 28 of 870
MS patients (3.3%). In a larger analysis of 14 trials and
,958 patients, Kastrati et al. (12) also evaluated a primary
nd point of all-cause mortality during a mean follow-up of
2.1 to 58.9 months. They also found no difference in the
ncidence of death or the combined end point of death or
nfarction (Fig. 1). In addition, using the combined end
oint of death, infarction, or reintervention, SES was
ssociated with marked improvement in outcomes (HR
.43, 95% CI 0.34 to 0.54). An important finding in this
tudy was that although the overall risk of ST was not
ifferent between SES and BMS, there was “evidence of a
light increase in ST with SES after the first year” (12).
The outcomes with SES, PES, and BMS were evaluated by
tone et al. (13) and Mauri et al. (10). Stone et al. (13)
valuated the same 4 SES trials as Spaulding et al. (14) and
hen included 5 additional trials of 3,513 patients randomly
ssigned to PES or BMS (Fig. 2). The primary end point of
he analysis was 4-year safety and efficacy. The 4-year target
essel revascularization rates were markedly reduced irrespec-
ive of whether SES or PES was used. In addition, the rate of
eath or infarction was not different between DES and BMS.
f interest was the finding that although overall ST through 4
ears was not different with DES versus BMS, beginning after
year ST was more frequent after DES. No differences in
eath or myocardial infarction were observed. In the final
tudy, Mauri et al. (10) specifically evaluated ST in randomized
rials of both SES and PES versus BMS using both the
riginal protocol definitions and the ARC definitions. In these
andomized trials with carefully selected patients and lesions,
epending upon the definition used the absolute frequency of
T varied and was highest with the most inclusive definition.
he authors concluded that using the ARC definition of
efinite or probable ST provided the best approximation of the prue incidence of the phenomenon. With this definition, no
ignificant differences between DES and BMS were observed.
In nonrandomized registry experiences, particularly those
ncluding longer-term follow-up, the incidence of ST has
een variable but appears to be slightly higher than observed
n randomized controlled trials. In a 2-center registry with
-month follow-up, Iakovou et al. (3) observed a 1.3%
ncidence, whereas in the RESEARCH (Rapamycin-
luting Stent Evaluated at Rotterdam Cardiology Hospital)
nd T-SEARCH (Taxus Stent Evaluated at Rotterdam
ardiology Hospital) registries the incidence was 1.0% (28).
n the e-Cypher (Cypher Sirolimus-Eluting Stent) post-
arket surveillance study on an “all comers” registry of
5,000 patients (35), the ST rate at 1 year was 0.87%. In the
ntegrated TAXUS program involving over 3,400 patients,
he total rate of ST to 3 years was 1.2% with PES versus
.7% with BMS. After Taxus stent deployment, 50% of ST
ere observed within 30 days; the remainder occurred
etween 30 and 180 days (36). Given the fact that ST may
Figure 1 Effect of SES Versus BMS on Subsequent
Death or Survival Free of Infarction
An analysis of 14 trials in 4,958 patients undergoing percutaneous coronary
intervention with either sirolimus-eluting stents (SES) or bare-metal stents
(BMS). There is no statistically significant difference in subsequent mortality
(A) or survival free of myocardial infarction (B). Used with permission from
Kastrati et al. (12).resent as sudden death, cause of death was studied in 4
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Thrombosis and DES: An Objective Appraisal July 10, 2007:109–18andomized Cypher stent trials involving 1,748 patients
37). In that analysis, total mortality was slightly increased
n patients who received the SES (vs. BMS), but that was
he result of an increase in noncardiac mortality in the 2
mallest studies (RAVEL [Randomized Comparison of a
irolimus Eluting Stent With a Standard Stent for Coro-
ary Revascularization] and e-SIRIUS [Sirolimus-Eluting
tent in Coronary Lesions]) (Fig. 3). When cardiac deaths
lone were analyzed, no difference in frequency was seen in
Figure 2 The 4-Year Follow-Up of Randomized Trials of SES Ver
At 4 years of follow-up, there is a slight but nonsignificant difference in mortality fo
bare-metal stents (BMS) but no difference in myocardial infarction. The beneficial
revascularization) remain. Used with permission from Stone et al. (13).atients treated with DES or BMS. oOther registry experiences have also become available.
illiams et al. (38) reported on 6,906 patients undergo-
ng PCI at 140 medical centers from January to June
005. Bare-metal stents were used in 397, SES in 3,873,
nd PES in 2,636 patients. They found that although the
nadjusted 1-year rates of death and myocardial infarc-
ion were higher with BMS than DES, after adjustment
he rates were not significantly different. Stent thrombo-
is occurred with 0.8% of BMS, 0.5% of SES, and 0.8%
MS and PES Versus BMS
sirolimus-eluting stents (SES) (A) and paclitaxel-eluting stents (PES) (B) versus
of both drug-eluting stents in reducing procedures for restenosis (target lesionsus B
r both
effectf PES.
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July 10, 2007:109–18 Thrombosis and DES: An Objective AppraisalRecently, the results of the Swedish Coronary Angiogra-
hy and Angioplasty Registry have been published and
ncluded 6,033 patients with DES and 13,738 patients with
MS (15). The primary outcome analysis was death and
nfarction. During 3 years of follow-up, there was no
ifference in the composite of death and infarction between
he 2 groups. There was a bimodal distribution of events: at
months, the event rate was lower with DES. After 6
onths, however, patients with DES had higher events.
fter 6 months, patients with DES experienced death
nd/or infarction at a rate of 0.5% to 1.0% higher per year.
f interest, the marked improvement in need for new
evascularization procedures seen with other studies of DES
as not seen: of patients with DES, 14.7% underwent new
ercutaneous coronary interventions compared with 14.5%
f BMS patients. The basis for the differences between this
tudy and the DEScover (Drug-Eluting Stent) Registry (38)
f 6,906 patients is unclear but may relate to length of
Figure 3 Cause of Death in Patients
Randomized to SES Versus BMS
Kaplan-Meier curves of survival in patients randomized to control bare-metal
stents (BMS) versus sirolimus (Cypher)-eluting stents (SES). The total mortality
was slightly increased in the SES patients (A) but there was no difference in
cardiac mortality (B). Used with permission from Holmes et al. (37).ollow-up available or other factors. nIn higher-risk patient/lesion subsets, the incidence of ST
ay be increased. This may relate to the specific drug as well
s to differences in drug diffusion that depend on the
resence and amount of organized thrombus (39). The
YPHOON (Trial to Assess the Use of the Cypher Stent
n Acute Myocardial Infarction Treated With Angioplasty)
tudy (40) randomized 700 patients with acute infarction to
ither SES or BMS. The overall incidence of ST was 3.4%
or SES and 3.6% for BMS. In a similar randomized study
f 423 patients with acute infarction, the SESAMI (Siroli-
us Stent Versus Bare Stent in Acute Myocardial Infarc-
ion) investigators observed ST in 3.1% of SES versus 3.7%
f BMS (41). Although it makes intuitive sense that
igher-risk patients would have more frequent ST, the data
re not all concordant. For example, the PASSION
Paclitaxel-Eluting Versus Uncoated Stents in Primary
ercutaneous Coronary Intervention) trial reported 619
atients with ST-segment elevation myocardial infarction
andomized to either PES or BMS (42). Acute ST occurred
n only 1 patient (0.3%) in the PES group. Subacute ST (1
o 30 days after the procedure) occurred in 1 patient (0.3%)
n the PES group and 3 patients (1.0%) in the BMS group.
ate ST (after 30 days) occurred in 1 patient in the PES
roup and none in the BMS group. The reasons for
pparent discordance in the incidence of ST (for both BMS
nd DES) between the PASSION and the TYPHOON or
ESAMI trials are unclear but may in part be related to
ifferences in definition and/or requirement for angio-
raphic documentation.
An overriding concern regarding ST is not so much the
arly incidence, which has been reasonably well studied, but
he potential long-term continuing risk that patients may
ace, especially after DES deployment. The BASKET-
ATE (Basel Stent Kosten Effektivitats Trial-Late) study
valuated this issue in 826 patients randomized in a 2:1
ashion to receive DES or BMS (43). Discontinuation of
lavix (clopidogrel bisulfate) at 6 months was not specified
y protocol, and the study was not designed primarily to
etect differences in ST. Between 7 and 18 months of
ollow-up, the rates of nonfatal infarction and death were
ncreased in the DES group (Fig. 4) although the absolute
requency was low. In addition, there was an imbalance in
T and thrombus-related events.
It is now clear from a few limited series with long-term
ollow-up that late and even very late ST may occur with
oth BMS and DES. As already mentioned, recent patient
ooled analyses (12) document some evidence of a numeric
xcess in ST after 1 year with DES. The focus now is to
inimize the risk of this occurrence with either BMS or
ES. Should the incidence of late ST be found to be small
ut continuous after DES, the challenge will be to mitigate
his risk given the known benefits of these devices in terms
f their efficacy in reducing clinical and angiographic reste-
osis (44,45).
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Thrombosis and DES: An Objective Appraisal July 10, 2007:109–18athology of ST
here is limited information about the histopathology
nderlying ST (5–8,24,46). A recent autopsy study (8)
dentified several important observations, including: 1) DES
ere characterized by persistent fibrin deposition (indicative
f delayed healing) as well as reduced endothelialization
ompared with BMS (p  0.0001); and 2) other factors
ssociated with late ST included local tissue hypersensitivity
eaction, placement of the stent in ostial and/or bifurcation
tenoses, incomplete stent apposition (malapposition), in-
tent restenosis, and stent penetration of the necrotic core of
he underlying plaque.
isk Factors for ST
ny study of ST is complicated by the fact that there are
Figure 4 Follow-Up of Events
Occurring in the BASKET-LATE Study
Major cardiac events during 7- to 18-month follow-up document no increase in
fatal myocardial infarction (MI) (A). There is a nonstatistical increase in the
rate of late stent thrombosis (B). BASKET-LATE  Basel Stent Kosten Effektivi-
tats Trial-Late. Used with permission from Pfisterer et al. (43). BMS  bare-
metal stents; DES  drug-eluting stents; MACE  major adverse cardiac
events.ultiple risk factors, including patient-, lesion-, and brocedure/device-related variables as well as compliance
ith, or resistance to, antiplatelet agents (5,7–9,46–55).
ultiple angiographic, procedural, and patient demo-
raphic factors associated with BMS thrombosis have been
dentified (47). Thrombosis after DES deployment has been
ssociated with the presence of renal insufficiency, diabetes,
nd depressed left ventricular function as well as stent
ength, bifurcation target stenosis, and stent overlap.
ntravascular ultrasound (IVUS) evaluation (51,52,56)
as identified other factors (lower minimum stent cross-
ectional area, reduced stent expansion, and residual signif-
cant stenosis) related to DES thrombosis. In addition,
nterruption or discontinuation of dual antiplatelet therapy
as been associated with thrombosis of DES, even late after
eployment.
An early report of 4 patients (4) documented angio-
raphic ST which occurred “soon after antiplatelet therapy
as interrupted” between 335 and 442 days after stent
eployment (2 Taxus and 2 Cypher stents). Each of these 4
atients experienced an acute ST myocardial infarction
elated to the ST. A subsequent report from the same
enters suggested that the incidence of late angiographic ST
fter DES deployment was approximately 0.35% (27). In
he large, 2-center experience published by Iakovou et al.
3), late ST (30 days to 9 months) was observed in 0.5% of
ypher- and 0.8% of Taxus-treated patients, and premature
iscontinuation of antiplatelet therapy was the most signif-
cant single factor implicated in the occurrence of either
ubacute or late ST. In the recent analysis by Mauri et al.
10) of SES, 2 of 9 patients with sirolimus-eluting ST and
of 12 patients with bare-metal ST after 30 days were
eceiving dual antiplatelet therapy.
It must be remembered that late ST is a rare event. An
mportant missing piece of information relates to the
umber of patients who discontinue dual antiplatelets after
or 6 months after DES implantation but do not develop
T. Irrespective of that, the recurrent theme of antiplatelet
herapy discontinuation raises important issues. Although
he current instructions for use of the 2 approved DES
ecommend dual (aspirin  thienopyridine) antiplatelet
herapy for 3 months (Cypher) or 6 months (Taxus), the
ore protracted persistent risk for ST raises the question of
hether combination antiplatelet therapies should be con-
inued indefinitely (57). Indeed, a recent report suggested
hat early (30 days) discontinuation of thienopyridine
herapy is associated with a highly significant (p  0.001)
ncrease in mortality to 1 year after DES deployment for
T-segment elevation myocardial infarction (58). Although
he benefit of extended clopidogrel (dual) antiplatelet ther-
py beyond 6 months has been debated (43,59), recent data
uggest that extension of dual therapy beyond 6 months and
ven 1 year is associated with significant clinical benefit
43,60). Indeed, in a nonrandomized clinical experience
ith follow-up to 2 years after stent deployment, treatment
ith a DES with continued aspirin and clopidogrel therapy
eyond 1 year was associated with a survival advantage as
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July 10, 2007:109–18 Thrombosis and DES: An Objective Appraisalell as survival free of death and myocardial infarction at 24
onths (60). These data argue for longer duration clopi-
ogrel therapy in patients treated with DES (57,61,62). In
his context, a recent American Heart Association Science
dvisory (57) has recommended continuation of dual anti-
latelet therapy for “at least 1 year” and deferral of elective
urgical procedures for this time frame as well. Despite these
ata, the optimal duration of dual antiplatelet therapy will
nly be determined by large-scale scientifically controlled
tudies.
Dual antiplatelet therapy may also be associated with
conomic challenges as well as bleeding risk compared with
spirin alone. Thus, continuation of dual antiplatelet ther-
py in patients at low risk for ST is problematic because it
ight be associated with increased bleeding. Accordingly,
ny incremental risk of bleeding must be weighed against
he incidence of ST, both of which are very infrequent (57).
Dual antiplatelet therapy may be discontinued for the
erformance of noncardiac surgical procedures or for cost
onsiderations in addition to bleeding. The required dura-
ion of antiplatelet therapy has become a significant factor in
ndertaking percutaneous coronary intervention in patients
ith substantial and complex comorbidities who are likely
o need subsequent medical attention over the ensuing years.
n those patients, estimation of ST risk is crucial, particu-
arly 1 year after initial implantation.
Although antiplatelet therapy discontinuation has been a
ommon theme in most clinical series of DES, this single
actor does not completely explain the phenomenon (57). In
lmost one-half of reported ST cases, antiplatelet therapy
iscontinuation does not appear to be implicated, and other
actors (renal failure, treatment of bifurcation lesions, dia-
etes mellitus, decreased ejection fraction, increasing stent
ength, and clopidogrel nonresponsiveness) appear to be
perative (8,9,50).
Patient and lesion complexity are also important consid-
rations. In the RAVEL study (63) of patients with rela-
ively simple lesions in a single vessel, ST rate after 5 years
as 0 in both the SES and BMS arms of the study (P.W.
erruys, personal communication, 2006). In the ARTS
Arterial Revascularization Therapies Study) I multivessel
tenting study using BMS, the thrombosis rate at 30 days
as 2.8%, whereas in the more recent ARTS II study using
ES it was only 0.8% (64). Short-term studies of new
evices in noncomplex lesions are, therefore, unlikely to
eflect the true risk of ST.
reventive Strategies
ecause the etiology of ST is multifactorial, strategies aimed
t its prevention should be multimodal as well. To be
ffective, such strategies should include:
. Optimizing stent implantation. Selection of the ap-
propriate diameter and length of stent to both optimally
cover the target lesion and appropriately expand the
reference vessel is crucial. Placement of excessively longDES (“overstenting” relative to target lesion) should be
avoided. Residual stent marginal dissections or signifi-
cant stenoses proximal or distal to the target lesion
should be treated. Suboptimal under- or overdeploy-
ment of stent diameter, which has been associated with
increased risk for ST, should be avoided. Intravascular
ultrasound may be useful in optimizing deployment
results. Indeed, IVUS analyses have demonstrated that
both Cypher and Taxus stents achieve only 75%  10%
of predicted minimal stent diameter and 66%  17% of
predicted minimum stent area (65,66). Approximately
25% of both stent types implanted into 3.0-mm vessels
do not achieve a minimum stent area 5.0 mm2 using
manufacturer-supplied compliance charts to target final
stent dimensions based on stent size and inflation
pressure (65,66). Subsequent ST has been associated
with both stent underexpansion and a lower minimum
stent area. Some specific techniques may be associated
with higher rates of ST (67). It is important to remem-
ber that the need for a specific technique, e.g., “stent
crush,” may just be a marker for a stenosis at high risk
for subsequent ST or other adverse events. It is also
possible that different DES are associated with different
risk for subacute closure (68).
. Adjunctive therapy. Dual antiplatelet therapy (aspirin
plus thienopyridine) after DES implantation is crucial.
Recently, the recommendation has been to extend this
therapy for up to 12 months in patients at low risk for
bleeding events (57). Whether or not longer durations
of dual antiplatelet therapy will be of actual benefit is
unclear, although clinical practice patterns have shifted
toward this direction, particularly in patients felt to be at
low risk of bleeding. The length of this extended
therapy remains the subject of considerable debate and
concern. There has been considerable interest in iden-
tifying the specific smaller group of patients at increased
risk of ST. Preliminary data suggest that “triple” anti-
platelet therapy (adding 100 mg cilostazol orally twice
daily to aspirin plus thienopyridine) may be associated
with a reduction in major adverse cardiovascular events,
including ST, and may be a therapeutic option for
patients at high risk for ST (69). Similarly, the admin-
istration of 150 mg clopidogrel daily may be considered
for patients at high risk for ST or those who are
clopidogrel hyporesponsive (50% platelet inhibition).
This treatment option has been incorporated into the
American College of Cardiology/American Heart As-
sociation clinical practice guideline recommendations
(class IIa recommendation) (70). In patients who either
will not (noncompliance, cost considerations) or cannot
take extended dual antiplatelet therapy, BMS deploy-
ment should be used preferentially, particularly where
the magnitude of benefit from DES compared with
BMS is small (e.g., large vessel diameter with short stent
length).
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ntiplatelet therapy prematurely within 3 to 6 months of
ES implantation is difficult. Interruption of antiplatelet
herapy is usually prompted by the requirement for a
oncardiac surgical procedure or, less commonly, by a
linically significant bleeding event. In cases where surgery
s required, the surgeon should be consulted to determine
he absolute necessity for discontinuing dual antiplatelet
herapy. If at all possible, temporary interruption of clopi-
ogrel therapy (stop 5 days before and restart 48 h after
urgery) perioperatively without discontinuation of daily
spirin therapy (81 mg) should be attempted. There are no
ata to support interim perioperative therapies such as
ow-molecular-weight heparin or platelet glycoprotein IIb/
IIa receptor inhibitors to reduce the risk of ST during
iscontinuation of oral antiplatelet therapies. If a gradient
or continued risk of very late thrombosis with DES is
ocumented, this will significantly affect patient care. Fi-
ally, much less is known regarding late thrombotic risk
fter deployment of newly available DES platforms outside
f the U.S. (71). The risk of thrombosis as well as optimal
uration of dual antiplatelet therapy should optimally be
ssessed on an individual basis for each device.
uture
uture objectives for reducing risk of ST and/or the require-
ent for extended (indefinite) dual antiplatelet therapy
nclude evolutionary improvements in both drug-eluting
tent platforms and adjunctive pharmacotherapies.
Efforts to reduce risk of ST have focused on the devel-
pment of more biocompatible or biodegradable polymers
or drug elution. New platforms with reduced polymer
urface area (reservoirs) are in clinical testing. Whether a
maller amount of polymer or a bioabsorbable polymer will
esult in less ST will require the study of many more patients
ith more complex lesions and longer-term follow-up.
ther strategies have been aimed at enhanced healing (72),
ncorporating antithrombotic medications into the polymer
oating, and complete elimination of the persistent metal
lloy prothesis with biodegradable stent platforms (73).
ong-term follow-up will be necessary to fully assess safety
s well as efficacy.
ew Adjunctive Pharmacotherapies
he issue of hyporesponsiveness or resistance of platelets to
harmacologic treatment has received considerable atten-
ion (74–79). It must be remembered that the extension
rom “in vitro hyporesponsiveness” to “clinical hyporespon-
iveness” is a long leap, particularly because the incidence of
n vitro hyporesponsiveness is much higher than the very
ow rate of ST. Clopidogrel (76–78) hyporesponsiveness
as been correlated with adverse ischemic events, including
T. Although an increase in the oral loading dose of
lopidogrel from 300 to 600 mg can reduce the prevalence
f hyporesponsiveness as well as accelerate the time coursend enhance the magnitude of platelet inhibition achieved,
arked variability in individual patient response persists
80).
Novel thienopyridine derivatives (81,82) which bind the
latelet P2Y12 receptor are in development specifically to
ddress the limitations of clopidogrel.
onclusions
tent thrombosis is an infrequent but very severe compli-
ation of both BMS and DES. Acute ST may be the result
f technical factors; the solution for this requires optimal
eployment strategies. Late ST appears to be multifactorial
n its etiology and thus requires a multifaceted solution.
lthough infrequent in occurrence, the consequences of late
T are frequently catastrophic and are just cause for con-
ern. Specific patient- and target lesion-related as well as
rocedural factors which predispose to drug-eluting ST
ave been identified and must be kept in mind. Similarly,
igilance in maintenance of dual antiplatelet therapy is
andatory. More data are required to determine the opti-
al duration of dual antiplatelet therapy, which may ulti-
ately be determined to be individual patient specific.
lthough there may be a difference in the time frame of ST
etween BMS and DES, at 4 years of follow-up in carefully
elected patients, there is no difference in the hard end point
f death and myocardial infarction. Longer-term studies of
years or even longer of DES in unselected patient
opulations are required to fully study the issues of this
omplex problem. Finally, advances in stent platforms for
rug elution as well as adjunctive pharmacotherapies may be
romising ways to enhance the long-term safety of DES.
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